

Thursday, 9 February 2023

	Plenary room Rotterdam Hall	Industry Theatre Exhibition Area	Exhibition Area
12:00			Registration & Badge Collection
12:15			
12:30			
12:45			
13:00	Opening Ceremony		
13:15	Clinical Indications I Lymphomas		
13:30			
13:45			
14:00			
14:15			
14:30			
14:45			
15:00	Clinical Indications II Acute & Chronic Leukaemias		
15:15			
15:30			
15:45			
16:00			
16:15			
16:30		Novel manufacturing technologies that enable advanced T cell generation by Bristol Myers Squibb	Coffee Break
16:45			
17:00	Best Abstract Session & Awards		
17:15			
17:30	Keynote Lecture: Maria Themeli		
17:45			
18:00			
18:15	Satellite Symposium Optimizing CAR T cell therapy experience in the real world: an outside-the-box discussion by Bristol Myers Squibb		
18:30			
18:45			
19:00			Welcome Reception Poster exhibition Meet the Expert Sessions
19:15			
19:30			
19:45			
20:00			
20:15			
20:30			

Friday, 10 February 2023

	Plenary room Rotterdam Hall	Breakout room Mees Room	Industry Theatre Exhibition Area	Exhibition Area
09:00	Keynote Lecture: Tom Whitehead			
09:15				
09:30				
09:45				
10:00	Clinical Indications III Multiple Myeloma	Opening and Session 1		
10:15				
10:30				
10:45				
11:00				Coffee Break
11:15				
11:30	Clinical Indications IV Solid Tumors & Keynote lecture: Carl June	Session 2		
11:45				
12:00				
12:15		Session 3		
12:30				
12:45				
13:00				
13:15			Kite: Leader in cell therapy	Lunch Break
13:30	Bringing CAR T into second line in DLBCL Satellite symposium sponsored by Kite			
13:45				
14:00				
14:15				
14:30	Patient perspective on CAR-T Round table	Session 4		
14:45				
15:00	Keynote Lecture: Marcela Maus			
15:15		Session 5		
15:30	CAR-T Innovation Pipeline			
15:45				
16:00				
16:15				
16:30				
16:45				Coffee Break
17:00				
17:15		Session 6 and closing		
17:30	Best Abstract Session			
17:45				
18:00				

Saturday, 11 February 2023

	Plenary room Rotterdam Hall	Breakout room Mees Room	Exhibition Area	
08:00				
08:15				
08:30	New Academic Initiatives & CAR-T Therapy Networks	Clinical Management of CAR-T Patients		
08:45				
09:00				
09:15				
09:30				
09:45	CAR-T Cell Therapy expands the horizon for patients with Multiple Myeloma Satellite Symposium by Janssen			
10:00				
10:15				
10:30				
10:45				
11:00	Advanced concepts for CAR-T manufacturing	Toxicity Management		
11:15				
11:30				
11:45				
12:00				
12:15	International Session Access to CAR-T on a Global Scale	Failure of CAR-T What is next?		
12:30				
12:45				
13:00				
13:15			Lunch boxes delivery	
13:30	Best Abstract Session			
13:45				
14:00	Keynote Lecture: Michel Sadelain			
14:15				
14:30	Closing Remarks			

Thursday, 9 February 2023

Physicians' sessions
Rotterdam Hall

13:00 - 13:15	Opening Ceremony Anna Sureda (ES) & Michael Hudecek (DE)	
13:15 - 14:45	Session 1: Clinical Indications I – Lymphomas Chair: Marie Jose Kersten (NL) & Catherine Thieblemont (FR)	
13:15-13:35	Large B Cell Lymphoma (LBCL)	Anna Sureda (ES)
13:35-13:55	Mantle Cell Lymphoma (MCL) / Follicular Lymphoma (FL)	Ulrich Jaeger (AT)
13:55-14:20	Resistance	Marco Ruella (US)
14:20-14:45	The role of the intestinal microbiome in cancer immunotherapy	Marcel Van den Brink (US)
15:00 - 16:30	Session 2: Clinical Indications II - Acute & Chronic Leukaemias Chairs: Annalisa Ruggeri (IT) & John Gribben (UK) & Stephan Mielke (SE)	
15:00 – 15:20	Acute Lymphoblastic Leukemia (ALL)	André Baruchel (FR)
15:20 – 15:45	Novel targets and technologies for CAR-T cells in AML	Michael Hudecek (DE)
15:45 – 16:10	Chronic Lymphocytic Leukemia (CLL)	John Gribben (UK)
16:10 – 16:30	T-cell Acute Lymphoblastic leukemia (T-ALL)/Treating T-Cell Non-Hodgkin Lymphoma (T-NHL)	Maksim Mamonkin (US)
16:30 – 17:00	Coffee break	
16:35 - 16:55	Industry Theatre: Novel manufacturing technologies that enable advanced T cell generation by Bristol Myers Squibb Presented by Mateusz Poltorak (DE) <i>“Cellular therapies have proven their therapeutic benefit in various hematological diseases and the recent development of CAR T-cell therapies highlight their curative potential. However, the generation of cellular therapies remains time consuming and cumbersome, which has created challenges especially in the commercial setting with ramping up manufacturing capacity and entering in new markets. New cellular therapy concepts such as CAR NK cells or allogeneic CAR T-cells may provide solutions to these bottle necks given their off-the-shelf administration, although their efficacy still needs to be proven in larger clinical studies. Juno Therapeutics GmbH, a BMS company, is currently pursuing novel strategies to shorten manufacturing times and to ease manufacturing ramp up. The presentation will focus on utologous CAR T-cells and innovative ways of manufacturing those with focus on cell selection and activation to reduce turnaround time and manufacturing costs as well as optimize drug product quality.”</i>	
17:00 – 17:30	Best Abstract Session & Awards Chairs: Anna Sureda (ES) & Michael Hudecek (DE)	
17:00 – 17:10	CAR T Cells Targeting Tumor and Stroma in PDACAabstract	Marc Wehrli (US)
17:10 – 17:20	Single-cell Dissection of Anti-BCMA CARs in MMAabstract	Vladan Vucinic (DE)
17:20 – 17:30	IF-BETTER-gated CAR T Cells to Safely Target AML with Minimal Escape	Sascha Haubner (US)
17:30 – 18:00	Keynote Lecture Chairs: Alejandro Madrigal (UK) & Alina Daniela Tanase (RO) Bringing CAR T to the next generation for efficacy and safety Maria Themeli (NL)	
18:15 – 19:00	Satellite Symposium Optimizing CAR T cell therapy experience in the real world: an outside-the-box discussion by Bristol Myers Squibb Chair: Salomon Manier (France) Marion Subklewe (Munich, Germany) Doris Hansen (United States)	
19:00 – 19:30	Meet the experts' sessions Marco Ruella Carl June Claire Roddie	Leeuwen Room I Goudriaan Room II Industry Theatre
19:00 – 20:00	Welcome Reception & Poster Exhibition	Foyer

Friday, 10 February 2023

Joint session Rotterdam Hall

9:00 – 9:45

Keynote Lecture

Chair: Michelle Kenyon (UK) & Michael Hudecek (DE) & Anna Sureda (ES) & Carl June (US)
Journey to CAR-T Cell Therapy & Beyond, Emily Whitehead's Story Tom Whitehead (US)

Physician's sessions Rotterdam Hall

10:00 – 11:00

Session 3: Clinical Indications III - Multiple Myeloma

Chair: Ibrahim Yakoub-Agha (FR) & Meral Beksac (TR) & Paula Rodriguez Otero (ES)

10:00 – 10:20

Overview

Hermann Einsele (DE)

10:20 – 10:40

CAR T myeloma ; biomarkers, PK, risk factors

Ibrahim Yakoub-Agha (FR)

10:40 – 11:00

AR1cel in MM/Amyloidosis

Carlos Fernandez de Larrea (ES)

11:00 – 11:30

Coffee break

11:30 – 13:00

Session 4: Clinical Indications IV - Solid Tumors & Keynote lecture

Chair: Fabio Ciceri (IT) & Annette Künkele (DE)

11:30 – 12:00

Keynote lecture on PSMA/Other solid tumors

Carl June (US)

12:00 – 12:20

Solid tumor pipeline

Sonia Guedan (ES)

12:20 – 12:40

Advancing CAR T Cell Therapy for Glioblastoma

Christine Brown (US)

12:40 – 13:00

Paediatrics CAR-Ts

Concetta Quintarelli (IT)

13:00 – 14:30

Lunch break | Visit exhibition | Networking

13:05 - 13:25

Industry Theatre | Kite: Leader in cell therapy

Leader in cell therapy

Dick Sundh

13:30 – 14:15

Bringing CAR T into second line in DLBCL | Satellite symposium sponsored by Kite

Chair: Tom van Meerten (NL)

13:30 – 13:33

Introduction to the symposium

13:33 – 13:48

Defining the unmet need in second-line DLBCL

Wendy Osborne (UK)

13:48 – 14:08

How has CAR T changed the second-line DLBCL treatment landscape?

Tom van Meerten (NL)

14:08 – 14:13

Q&A

14:13 – 14:15

Close

14:30 – 15:00

Session 5: Patient perspective on CAR-T Round table

Chair: Natacha Bolaños (ES) & Solène Clavreul (FR)

Roundtable discussion

Martine Elias (CA)

Kenneth Casler (FR)

15:00 – 15:30

Keynote Lecture

Chairs: Chiara Bonini (IT) & Dirk Busch (DE)

Mechanisms driving CAR T cells

Marcela Maus (US)

15:30 – 16:30

Session 6: CAR-T Innovation Pipeline

Chairs: Maria Themeli (NL) & Ciprian Tomuleasa (RO)

15:30 – 15:50

Pre-selection of naive T cells and tumor deglycosylation to improve CAR-T cell therapy

Monica Casucci (IT)

15:50 – 16:10

Pooled CRISPR Knockin Screens: Reprogramming Therapeutic T Cells

Franziska Blaeschke (US)

16:10 – 16:30

Artificial Intelligence for CAR-T

Qasim Rafiq (UK)

16:30 – 17:00

Coffee break

17:00 – 18:10

Best Abstract Session

Chairs: Ulrich Jaeger (AT) & Sonia Guedan (ES)

17:00 – 17:10

Association of MTV and Clinical Outcomes in R/R LBCL (ZUMA-7)

Marie José Kersten (NL)

17:10 – 17:20

CD19-directed 1st CAR T Cells in Patients with Rel/Ref DLBCL

M. Lia Palomba (US)

17:20 – 17:30

ZUMA-5 3-year Follow-up: Axi-cel in Patients with R/R Inhl

Ibrahim Yakoub-Agha (FR)

17:30 – 17:40

ELARA Clinical Update + Biomarkers and PK

Catherine Thieblemont (FR)

17:40 – 17:50

EpCAM-directed CAR T-cells against Brain Metastases from Lung Cancer

Tao Xu (DE)

17:50 – 18:00

Psychosocial Experiences in Patients Receiving CAR-T Compared to Other Therapies

Natacha Bolaños (ES)

18:00 – 18:10

Ide-cel versus Standard Regimens in Triple-class-Exposed RRMM: Phase 3 KarMMa-3

Paula Rodriguez Otero (ES)

Friday, 10 February 2023

Joint session Rotterdam Hall

9:00 – 9:45

Keynote Lecture

Chair: Michelle Kenyon (UK) & Michael Hudecek (DE) & Anna Sureda (ES) & Carl June (US)
Journey to CAR-T Cell Therapy & Beyond, Emily Whitehead's Story Tom Whitehead (US)

Nurses' sessions Mees Room

10:00 - 11:00

Opening and Session 1

Chairs: Erik Aerts (CH) & Michelle Kenyon (UK)

10:00 – 10:05

Opening

10:05 – 10:15

Haematology Nurses and Healthcare Professionals (HNHCP) – CAR T-cell therapy learning program: a resource for healthcare professionals

Erik Aerts (CH)

10:15 – 10:20

IEC Forum

Ruth Clout (UK)

10:20 – 10:40

The nurse and the patient pathway

Rose Ellard (UK)

10:25 – 10:40

CAR T Cell therapy: past, present, future

Elaine Vickers (UK)

11:00 – 11:30

Coffee break

11:30 - 12:15

Session 2

Chairs: Ruth Clout (UK) & Rose Ellard (UK)

11:30 – 11:55

Disease update lymphoma, leukaemia and Myeloma

Ibrahim Yakoub-Agha (FR)

11:55 – 12:15

Horizon scanning: paediatrics

Marjola Gjergji (IT)

12:15 - 13:00

Session 3

Chairs: Ruth Clout (UK) & Rose Ellard (UK)

12:15 – 12:30

From prehab to rehab: nutritional support in patients treated with CAR-T therapy

Amanda Casirati (IT)

12:30 – 12:45

Adapted Physical Activity

Nicolas BreLOT (FR)

12:45 – 13:00

Prehab/ rehab psychology

Vera Hinderling-Baertschi (CH)

13:00 – 14:30

Lunch break | Visit exhibition | Networking

14:30 - 15:15

Session 4

Chairs: Ruth Clout (UK) & Rose Ellard (UK)

14:30 – 14:45

Early and late infections in patients undergoing CAR T-cell Therapy

Andriyana Bankova (CH)

14:45 – 15:00

Experiences of CAR T Cell Therapy: What Nurses report

Martina Spalt (AT)

15:00 – 15:15

Advance care planning

Jennifer Vidrine (UK)

15:15 - 16:30

Session 5

Chairs: Ruth Clout (UK) & Rose Ellard (UK)

15:15 – 15:35

Ethical considerations

Anna Castleton (UK)

15:35 – 15:55

CAR T-Cell Therapies: A Patient's Perspective

Jonathan Clark (NL)

15:55 – 16:05

CAR T-cell Therapy: Patients- and Family Caregivers'

Needs Post-treatment

Britt Snoek (NL)

16:05 – 16:15

Nutritional Status during CAR-T Therapy

Nicola Scott (UK)

16:15 – 16:30

Panel Discussion

16:30 – 17:00

Coffee break

17:00 - 17:45

Session 6 and closing

Chair: Erik Aerts (CH) & Michelle Kenyon (UK)

17:00 – 17:15

Delivering a single national adult CAR T service

Liz Higgins (IE)

17:15 – 17:30

Capacity building and future proofing

Peter Dreger (DE)

17:30 – 17:45

Closing remarksMichelle Kenyon (UK)

Erik Aerts (CH)

Saturday, 11 February 2023

Physicians' Sessions Rotterdam Hall

08:30 – 09:40

Session 7: New Academic Initiatives & CAR-T Therapy Networks

Chairs: Chiara Bonini (IT) & Natacha Bolaños (ES)

08:30 – 08:44

GoCART Initiative

Jürgen Kuball (NL)

08:58 – 09:12

The EBMT Registry: monitoring CAR-T Cells and IECs activities in Europe

Christian Chabannon (FR)

08:44 – 08:58

IMI EU T2EVOLVE

Carmen Sanges (DE)

09:12 – 09:26

Advanced Therapies Network Spain

Jose M. Moraleda (ES)

09:26 – 09:40

CAR-T Switzerland

Caroline Arber (CH)

09:40 – 09:45

Coffee delivery

09:45 - 10:30

CAR-T Cell Therapy expands the horizon for patients with Multiple Myeloma | Satellite Symposium by Janssen

Chair: Mohamad Mohty (FR)

09:45 – 09:50

Welcome and introduction

Mohamad Mohty (FR)

09:50 – 10:05

Where are we now with CAR-T cell therapy in MM?

Paula Rodriguez Otero (ES)

10:05 – 10:20

Where are we going with CAR-T cell therapy in MM?

Pieter Sonneveld (NL)

10:20 – 10:30

Panel discussion with Q&A | Closing remarks

10:40 - 11:50

Session 9: Advanced concepts for CAR-T manufacturing

Chairs: Halvard Bönig (DE) & Concetta Quintarelli (IT)

10:40 – 10:55

Overview

Ulrike Köhl (DE)

10:55 – 11:10

Point-of-care CAR-T manufacture

Alvaro Urbano Ispizua (ES)

11:10 – 11:25

Rapid CAR-T manufacture

Nina Worel (AT)

11:25 – 11:40

Point-of-care ATMP manufacture

Harry Dolstra (NL)

11:40 – 11:50

Panel discussion

12:00 - 13:10

Session 11: International Session - Access to CAR-T on a Global Scale

Chair: Christian Chabannon (FR) & Ulrike Köhl (DE)

12:00 – 12:12

South America

Vanderson Rocha (BR)

12:12 – 12:24

Central and Eastern Europe

Roman Hajek (CZ)

12:24 – 12:36

South Africa

Candice Hendricks (ZA)

12:36 – 12:48

Canada

Kevin Hay (CA)

12:48 – 13:00

India

Gaurav Narula (IN)

13:00 – 13:10

Roundtable discussion

Martine Elias (CA)

13:10 – 13:30

Lunch box delivery

13:30 - 14:00

Best Abstract Session

Chairs: Anna Sureda (ES) & Michael Hudecek (DE)

13:30 – 13:40

Third-generation TLR2 Co-stimulated CAR T-cells for B-cell Malignancies

Yasmin Nouri (NZ)

13:40 – 13:50

Impact of Gut Microbiota in the Efficacy of CART-cell Therapy

Mireia Uribe-Herranz (ES)

13:50 – 14:00

Dual CD30/PDL1 CAR-T Cell Strategy in Classic Hodgkin's Lymphoma

Vincenzo Maria Perriello (IT)

14:00 - 14:30

Keynote Lecture

Chairs: Anna Sureda (ES) & Michael Hudecek (DE)

Antigen sensitivity, persistence and gated control of CAR T cells Michel Sadelain (US)

14:30 - 14:45

Closing remarks

Anna Sureda (ES) & Michael Hudecek (DE)

Saturday, 11 February 2023

Physicians' Sessions Mees Room

08:30 - 09:40

Session 8: Clinical Management of CAR-T Patients

Chair: Arnon Nagler (IL) & Valentin Ortiz-Maldonado (ES)

08:30 – 08:40	Patient perspective: CAR-T Journey	Kenneth Casler (FR)
08:40 – 08:48	Car-HLH: A devastating complication following Chimeric Antigen Receptor T-cell (CAR-T cell) therapy	Muhammad Gohar Maqbool (UK)
08:48 – 09:00	Case presentation discussion: adult lymphoma <i>Panellists: Peter Dreger (DE) & Paolo Corradini (IT)</i>	
09:00 – 09:08	Successful Treatment of Romiplostim for Persistent Thrombocytopenia Following CAR-T Cell Therapy in Phi+ B-ALL: A Case Report	Julien Dereme (CH)
09:08 – 09:20	Case presentation discussion: adult ALL <i>Panellists: Mohamad Mohty (FR) & Claire Roddie (UK)</i>	
09:20 – 09:28	Myositis in a patient with relapsed/refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy	Sofía Huerga Domínguez (ES)
09:28 – 09:40	Case presentation discussion: Multiple Myeloma <i>Panellists: Paula Rodriguez Otero (ES) & Michel Delforge (BE)</i>	

09:40 – 09:45

Coffee delivery

Joint Session Rotterdam Hall

09:45 - 10:30

CAR-T Cell Therapy expands the horizon for patients with Multiple Myeloma | Satellite Symposium by Janssen

Chair: Mohamad Mohty (FR)

09:45 – 09:50	Welcome and introduction	Mohamad Mohty (FR)
09:50 – 10:05	Where are we now with CAR-T cell therapy in MM?	Paula Rodriguez Otero (ES)
10:05 – 10:20	Where are we going with CAR-T cell therapy in MM?	Pieter Sonneveld (NL)
10:20 – 10:30	Panel discussion with Q&A Closing remarks	

Physicians' Sessions Mees Room

10:40 - 11:50

Session 10: Toxicity Management (Cytopenias, COVID, CRS/ICANS Update)

Chairs: Zinaida Peric (HR) & Patrick Hayden (IE)

10:40 – 10:55	European Guidelines	Ibrahim Yakoub-Agha (FR)
10:55 – 11:10	Hematologic Toxicity	Marion Subklewe (DE)
11:10 – 11:25	COVID	Marie José Kersten (NL)
11:25 – 11:50	Panel discussion	

12:00 - 13:10

Session 12: Failure of CAR-T - What is next?

Chairs: Raffaella Greco (IT) & Natacha Bolaños (ES) & Koray Yalcin (TR)

12:00 – 12:10	Patient perspective: Fear of relapse	Natacha Bolaños (ES)
12:10 – 12:18	Case Presentation (MM): Sequential Therapy with Teclistamab after Failure of BCMA-directed CAR-T Therapy	Lukas Scheller (DE)
12:18 – 12:30	Case presentation: Multiple Myeloma <i>Panellists: Maria Victoria Mateos (ES) & Sophia Danhof (DE)</i>	
12:30 – 12:38	Case Presentation (ALL): Inotuzumab Ozogamicin Bridges to Allo-HSCT Post-CAR T-cell Relapse in BCP-ALL	Margo Aertgeerts (BE)
12:38 – 12:50	Case presentation discussion: Paediatric ALL <i>Panellists: Sara Ghorashian (UK) & Annette Künkele (DE)</i>	
12:50 – 12:58	Case Presentation (Lymphoma): AML after CAR-T Therapy in Relapsed High-grade Non-Hodgkin B Lymphoma	Juan Fco. López Rodríguez (ES)
12:58 – 13:10	Case presentation discussion: adult lymphoma <i>Panellist: Anna Sureda (ES) & Raffaella Greco (IT)</i>	